ESC 365 - Why atrial fibrillation duration should be an endpoint in atrial fibrillation ablation trials

ESC Professional Premium Access

Why atrial fibrillation duration should be an endpoint in atrial fibrillation ablation trials

Session: Management of atrial fibrillation: knowns and unknowns

Topic: Treatment

Speaker: Professor C. Blomstrom-Lundqvist (Orebro, SE)

Event: ESC Congress 2024

Congress Presentation

Add to my library

About the speaker

Professor Carina Blomstrom-Lundqvist

Orebro University Hospital, Orebro (Sweden)

40 presentations

8 followers

4 more presentations in this session

The three pillars of atrial fibrillation management

Speaker: Professor G. Lip (Liverpool, GB)

Will left atrial appendage occlusion replace oral anticoagulation?

Speaker: Professor M. Glikson (Jerusalem, IL)

Pulsed field ablation: should it replace radiofrequency and balloon cryoablation?

Speaker: Doctor T. De Potter (Aalst, BE)

Management of atrial fibrillation: knowns and unknowns - discussion

Access the full session

Management of atrial fibrillation: knowns and unknowns

Speakers: Professor C. Blomstrom-Lundqvist, Professor G. Lip, Professor M. Glikson, Doctor T. De Potter

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources